EGFR-variant non–small cell lung cancer (NSCLC) responds effectively to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).1 In some cases, treatment with a third-generation EGFR TKI, such as osimertinib, or a first-generation or second-generation EGFR TKI, like gefitinib, erlotinib, or afatinib, is the standard therapy for advanced NSCLC harboring activating EGFR variants, while osimertinib is a preferred option based on the superior brain activity.2,3. The gene discussed is EGFR; the disease is lung cancer.